Inherited defects of coagulation factor V: The thrombotic side

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 1, 2006, Pages 35-40

  Vos, H L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; RECOMBINANT PROTEIN;

DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IN VITRO STUDY; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN FUNCTION; REVIEW; THROMBOSIS; VEIN THROMBOSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 5 DEFICIENCY; GENETICS;

BLOOD COAGULATION DISORDERS, INHERITED; FACTOR V DEFICIENCY; HAPLOTYPES; HUMANS; THROMBOSIS; VARIATION (GENETICS);

EID: 33644869051     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01572.x     Document Type: Review

References (40)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
3. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
4. Nicolaes GAF, Dahlbäck B. Factor V and thrombotic disease. Description of a Janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-538.
5. Mann KG, Kalafatis M. Factor V: A combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
6. Castoldi E, Rosing J. Factor V Leiden: A disorder of factor V anticoagulant function. Curr Opin Hematol. 2004; 11: 176-81.
7. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: The hemorrhagic side. J. Thromb. Haemost 2006; 4, 26-34.
8. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A 1987; 84: 4846-50.
9. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004; 340: 783-95.
10. Montefusco MC, Duga S, Asselta R, Santagostino E, Malcovati M, Mannucci PM, Tenchini M. Allelic heterogeneity of severe Factor V deficiency. ISTH 2001, P1120 (2001).
11. Bossone A, Cappucci F, D'Andrea G, Brancaccio V, Cibelli G, Iannaccone L, Grandone E, Margaglione M. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation. Haematologica 2003; 88: 286-9.
12. Scanavini D, Girelli D, Lunghi B, Martinelli N, Legnani C, Pinotti M, Palareti G, Bernardi F. Modulation of factor V levels in plasma by polymorphisms in the C2 domain. Arterioscler Thromb Vasc Biol. 2004; 24: 200-6.
13. van der Neut Kolfschoten M, Dirven RJ, Poort SR, van Wijk R, Vos HL, Rosendaal FR, Bertina RM. Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V. J Thromb Haemost 2004; 2: 910-7.
14. Lunghi B, Scanavini D, Girelli D, Legnani C, Bernardi F. Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? J Thromb Haemost. 2005; 3: 415-6.
15. de Visser MCH, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost. 2000; 83: 577-82.
16. Jääskeläinen E, Toivonen S, Romppanen EL, Helisalmi S, Keski-Nisula L, Punnonen K, Heinonen S. M385T polymorphism in the factor V gene, but not Leiden mutation, is associated with placental abruption in Finnish women. Placenta 2004; 25: 730-4.
17. Hiyoshi M, Arnutti P, Prayoonwiwat W, Nathalang O, Suwanasophon C, Kokaseam R, Hashimoto S, Takubo T, Tagawa S, Fukui M, Tatsumi N. A polymorphism nt 1628G->A (R485K) in exon 10 of the coagulation factor V gene may be a risk factor for thrombosis in the indigenous Thai population. Thromb Haemost. 1998; 80: 705-6.
18. Le W, Yu JD, Lu L, Tao R, You B, Cai X, Cao WJ, Huang W, He RM, Zhu DL, Chen Z, Gong LS. Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population. Clin Genet. 2000; 57: 296-303.
19. Watanabe H, Hamada H, Yamada N, Sohda S, Yamakawa-Kobayashi K, Yoshikawa H, Arinami T. Association analysis of nine missense polymorphisms in the coagulation factor V gene with severe preeclampsia in pregnant Japanese women. J Hum Genet. 2002; 47: 131-5.
20. Faisel F, Romppanen EL, Hiltunen M, Helisalmi S, Laasanen J, Punnonen K, Salonen JT, Heinonen S. Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation. Eur J Hum Genet 2004; 12: 187-91.
21. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF. Survival advantage associated with heterozygous Factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-92.
22. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004; 32: S239-46.
23. Weiler H, Kerlin B, Lytle MC. Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Crit Care Med. 2004; 32: S233-8.
24. Lindqvist PG, Zöller B, Dahlbäck B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden - an evolutionary advantage? Thromb Haemost. 2001; 86: 1122-3.
25. Kostka H, Siegert G, Schwarz T, Gehrisch S, Kuhlisch E, Schellong S, Jaross W. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients. Thromb Res. 2000; 99: 539-47.
26. Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost. 1996; 75: 45-8.
27. Yamazaki T, Nicolaes GA, Sørensen KW, Dahlbäck B. Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. Blood 2002; 100: 2515-21.
28. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Bertina RM. The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181. Thromb Haemost 2003; 89: 429-37.
29. Miteva MA, Brugge JM, Rosing J, Nicolaes GA, Villoutreix BO. Theoretical and experimental study of the D2194G mutation in the C2 domain of coagulation factor V. Biophys J. 2004; 86: 488-98.
30. Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, Ferraresi P, Friso S, Corrocher R, Tans G, Bernardi F. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83: 362-5.
31. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
32. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg306->Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
33. Norstrøm E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002; 100: 524-30.
34. van der Neut Kolfschoten M, Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002; 13: 207-15.
35. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Tans G, Rosing J, Bertina RM. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679. J Biol Chem 2004; 279: 6567-75.
36. Mumford AD, McVey JH, Morse CV, Gomez K, Steen M, Norstrøm EA, Tuddenham EG, Dahlbäck B, Bolton-Maggs PH. Factor V I359T: A novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol. 2003; 123: 496-501.
37. Steen M, Norstrøm EA, Tholander AL, Bolton-Maggs PH, Mumford A, McVey JH, Tuddenham EG, Dahlbäck B. Functional characterization of factor V-Ile359Thr: A novel mutation associated with thrombosis. Blood 2004; 103: 3381-7.
38. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: Risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20: 1382-6.
39. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68: 978-89.
40. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, Cox DR. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307: 1072-9.